These studies clearly highlight trimetazidine as an anti-inflammatory medication peripherally
This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution
Or youll have better stamina as you dribble on the court
Journal of Physiology-Paris 87:313327 Sikiric P, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Pavlov KH (2018) Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157
Photograph it held up to a light